Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection DOI Open Access
Martina Bozhkova, С. В. Петров,

Tanya Velyanova

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 17, 2024

This case report aims to elucidate the unique clinical course of a 34-year-old male patient diagnosed with human immunodeficiency virus (HIV), chronic hepatitis C, and prior tuberculosis (TB) infections, who subsequently contracted COVID-19. Immunological assessments revealed profound immunosuppression, marked by decreased CD4+ T cells (0.037 x 10⁹/L), alongside mildly elevated IgG levels (16.701 g/L), reflecting both HIV-related non-adherence antiretroviral therapy (ART). Concurrently, tested positive for SARS-CoV-2. Imaging findings demonstrated overlapping characteristics TB Timely initiation specific therapy, supportive care optimized anti-TB regimens, was implemented. Despite patient's immunocompromised state complex medical history, he successfully recovered from Key factors contributing survival included early diagnosis treatment, comprehensive care, careful management drug interactions, potentially effective individual immune response. Notably, no typical features COVID-19 pneumonia were observed, suggesting that dual infection may have influenced presentation. underscores potential outcomes in individuals histories, including coexisting infections. Further research into interplay multiple infections such patients is warranted optimize strategies enhance our understanding within this distinctive population.

Language: Английский

COVID-19 related complications DOI
Muhamed Adilović

Progress in molecular biology and translational science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Therapeutic Approaches for COVID-19: A Review of Antiviral Treatments, Immunotherapies, and Emerging Interventions DOI Creative Commons

Maria João Vidal Alves,

Ruana Carolina Cabral da Silva, Sérgio de Sá Leitão Paiva Júnior

et al.

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: May 8, 2025

The coronavirus disease 2019 (COVID-19) global health crisis, caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), has presented unprecedented challenges to healthcare systems, leading rapid advances in treatment development. This review comprehensively examines current therapeutic approaches for managing COVID-19, including direct-acting antivirals, immunomodulators, anticoagulants, and adjuvant therapies, as well emerging experimental approaches. Direct-acting antivirals target various stages of viral life cycle, offering specific intervention points, while immunomodulators aim modulate host's immune response, reducing severity. Anticoagulant therapies address coagulopathy frequently observed cases, treatments provide supportive care improve overall outcomes. We also explore limitations implementing these treatments, such drug resistance, variable patient responses, access especially resource-limited settings. discusses future perspectives, potential next-generation vaccines, personalized medicine, collaboration shaping COVID-19 paradigms. Continuous innovation, combined with an integrated adaptable approach, will be crucial effectively mitigating impact pandemics.

Language: Английский

Citations

0
Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection DOI

Carolin M. Lieber,

Hae-Ji Kang,

Elizabeth B. Sobolik

et al.

Journal of Virology, Journal Year: 2024, Volume and Issue: 98(9)

Published: Aug. 29, 2024

Immunocompromised people are at high risk of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and progression to disease 2019 (COVID-19). However, the efficacy late-onset direct-acting antiviral (DAA) therapy with therapeutics in clinical use experimental drugs mitigate persistent viral replication is unclear. In this study, we employed an immunocompromised mouse model, which supports SARS-CoV-2 explore treatment options. Tandem immuno-depletion CD4

Language: Английский

Citations

2
Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection DOI Open Access

Carolin M. Lieber,

Hae-Ji Kang,

Elizabeth B. Sobolik

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 23, 2024

The immunocompromised are at high risk of prolonged SARS-CoV-2 infection and progression to severe COVID-19. However, efficacy late-onset direct-acting antiviral (DAA) therapy with therapeutics in clinical use experimental drugs mitigate persistent viral replication is unclear. In this study, we employed an mouse model, which supports explore treatment options. Tandem immuno-depletion CD4

Language: Английский

Citations

1
Commenting on baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study DOI Creative Commons
James Cheng‐Chung Wei,

Poi Kuo,

Po‐Cheng Shih

et al.

Critical Care, Journal Year: 2024, Volume and Issue: 28(1)

Published: Nov. 5, 2024

Language: Английский

Citations

1
Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection DOI Open Access
Martina Bozhkova, С. В. Петров,

Tanya Velyanova

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 17, 2024

This case report aims to elucidate the unique clinical course of a 34-year-old male patient diagnosed with human immunodeficiency virus (HIV), chronic hepatitis C, and prior tuberculosis (TB) infections, who subsequently contracted COVID-19. Immunological assessments revealed profound immunosuppression, marked by decreased CD4+ T cells (0.037 x 10⁹/L), alongside mildly elevated IgG levels (16.701 g/L), reflecting both HIV-related non-adherence antiretroviral therapy (ART). Concurrently, tested positive for SARS-CoV-2. Imaging findings demonstrated overlapping characteristics TB Timely initiation specific therapy, supportive care optimized anti-TB regimens, was implemented. Despite patient's immunocompromised state complex medical history, he successfully recovered from Key factors contributing survival included early diagnosis treatment, comprehensive care, careful management drug interactions, potentially effective individual immune response. Notably, no typical features COVID-19 pneumonia were observed, suggesting that dual infection may have influenced presentation. underscores potential outcomes in individuals histories, including coexisting infections. Further research into interplay multiple infections such patients is warranted optimize strategies enhance our understanding within this distinctive population.

Language: Английский

Citations

0